According to new research published today in the American Heart Association's flagship journal Circulation, women face a 20% increased risk of developing heart failure or dying within five years after their first severe heart attack compared with...
Moderna today announced that the primary efficacy analysis of their Phase 3 study of their vaccine candidate, mRNA-1273 conducted on 196 cases confirms the high efficacy observed at the first interim analysis. The data analysis indicates a...
A third COVID-19 vaccine, this one from AstraZeneca, reported Monday that late-stage trials showed that its COVID-19 vaccine with Oxford University was up to 90% effective in preventing disease.
The results are based on...
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for casirivimab and imdevimab to be administered together for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2...
Pfizer Inc. and its German partner, BioNTech SE will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2 against SARS-CoV-2, which will potentially enable...
In a press release issued today, Pfizer said that new test results show its coronavirus vaccine is 95% effective, is safe and also protects older people most at risk of dying — the last data needed to...
Moderna said its experimental coronavirus vaccine was nearly 95 percent effective in a pivotal study. The NIH-appointed Data Safety Monitoring Board (DSMB) informed Moderna that the trial has met the statistical criteria pre-specified in the study protocol for...
Delivery giant DoorDash Inc. is planning to sell its stock to the public, capitalizing on the growing trend of consumers embracing app-based deliveries with many at home during the pandemic.
The company made its...
Updated data from researchers at John Hopkins University showed 143,200 cases were added on Wednesday, topping the record set the day before by almost 3,000 cases. Wednesday was the fifth single-day case record in nine days.
In a note to clients Tuesday, SVB Leerink analyst Geoffrey Porges said
the recent results from Pfizer's early COVID-19 vaccine data should “boost
confidence of the general public in COVID vaccines, which should drive up the
early adoption rate.” The analysts see Pfizer’s...
Results from Zillow's Consumer Housing Trends Report show renters of color typically submit more applications — and pay more in application fees — before they secure...
A COVID-19 investigational vaccine, developed by City of Hope scientists and now licensed to GeoVax Labs Inc., produced a robust neutralizing antibody...
